A recombinant humanized antibody to Venezuelan equine encephalitis virus (VEEV) was constructed in a monocistronic adenoviral expression vector with a foot-and-mouth-disease virus-derived 2A self-cleavage oligopeptide inserted between the antibody heavy and light chains. After expression in mammalian cells, the heavy and light chains of the humanized antibody (hu1A4A1IgG1-2A) were completely cleaved and properly dimerized. The purified hu1A4A1IgG1-2A retained VEEV binding affinity and neutralizing activity similar to its parental murine antibody. The half-life of hu1A4A1IgG1-2A in mice was approximately 2 days. Passive immunization of hu1A4A1IgG1-2A in mice (50 microg/mouse) 24 h before or after virulent VEEV challenge provided complete protection, indicating that hu1A4A1IgG1-2A has potent prophylactic and therapeutic effects against VEEV infection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2010.06.038 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Food Safety Evaluation of Recombinant Humanized Type III Collagen Produced by Komagataella phaffii SMD1168-2COL3.
J Appl Toxicol
January 2025
College of Food Science and Nutritional Engineering, China Agricultural University, Beijing, China.
Collagens are biofunctional proteins that have been widely used in many fields, including biomedical, cosmetics, and skin care for their value in maintaining the integrity of cellular membranes. Collagens are also commonly consumed in foods and provide a source of protein and amino acids. As part of the safety assessment for this particular recombinant humanized type III (RHTypeIII) collagen produced by Komagataella phaffii SMD1168-2COL3, a series of toxicological tests were conducted.
View Article and Find Full Text PDF[Peripheral ulcerative keratitis associated with dupilumab: a case report].
Zhonghua Yan Ke Za Zhi
January 2025
Department of Ophthalmology,Beijing Hospital, National Center of Gerontology Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing100730,China.
Article Synopsis
- A 68-year-old male experienced irritation in both eyes, including symptoms like photophobia and tearing, after starting dupilumab for severe atopic dermatitis.
- He had a specific corneal ulcer in the right eye and a pannus in the left eye, but tests ruled out infections.
- Treatment with eye drops led to significant improvement, and follow-up revealed healing of the corneal lesions and improved vision.
Purpose: This study evaluates the efficacy of intravitreal injections (IVI) of faricimab in patients with neovascular age-related macular degeneration (nAMD) and retinal pigment epithelium detachment (RPED) resistant to other anti-VEGF agents.
Material And Methods: The study included 61 patients (61 eyes) with nAMD previously treated with aflibercept and/or brolucizumab IVIs. Three groups were formed: group 1 received aflibercept IVI (32 eyes), group 2 received brolucizumab IVI (14 eyes), and group 3 received aflibercept followed by brolucizumab IVI (15 eyes).
Ex vivo evaluation of the effect of plasma-derived factor VIII/von Willebrand factor in patients with severe hemophilia A on emicizumab prophylaxis.
Clin Exp Med
December 2024
Discovery Research, Scientific Innovation Office, Grifols, Palou 3, 08150, Parets del Vallès, Barcelona, Spain.
Hemophilia A (HA) patients under emicizumab prophylaxis may require the concomitant use of procoagulant factors for breakthrough bleedings or immune tolerance induction (ITI). The aim of this study is to evaluate the ex vivo procoagulant effect of plasma-derived FVIII concentrates containing von Willebrand factor (pdFVIII/VWF) in samples from patients with severe HA without inhibitors on emicizumab prophylaxis. Samples from healthy controls (HC) and HA patients were drawn in sodium citrate plus corn trypsin inhibitor tubes and spiked with increasing concentrations of pdFVIII/VWF concentrates (10-400 IU/dL) (Fanhdi/Alphanate, Grifols), activated prothrombin complex concentrate (aPCC, 0.
View Article and Find Full Text PDFWhat Is New in Morphea-Narrative Review on Molecular Aspects and New Targeted Therapies.
J Clin Med
November 2024
Department of Dermatology, Poznan University of Medical Sciences, 60-806 Poznan, Poland.
Article Synopsis
- Morphea, or localized scleroderma, is an autoimmune disease marked by excessive collagen buildup in the skin, with unclear causes that may include genetic, environmental, and epigenetic factors.
- Advances in medicine suggest genetic and epigenetic influences may significantly impact the disease's risk and progression, highlighting the role of factors like microRNAs and DNA methylation.
- New treatment options, including biological therapies and JAK inhibitors, show promise based on case studies, underscoring the need for further exploration of morphea's pathogenesis and treatment strategies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!